Literature DB >> 28601783

Potential impact of the Affordable Care Act's preventive services provision on breast cancer stage: A preliminary assessment.

Abigail Silva1, Yamile Molina2, Bijou Hunt3, Talar Markossian4, Nazia Saiyed3.   

Abstract

INTRODUCTION: The Affordable Care Act's (ACA) preventive services provision (PSP) removes copayments for preventive services such as cancer screening. We examined: 1) whether a shift in breast cancer stage occurred, and 2) the impact of the provision on racial/ethnic disparities in stage.
MATERIALS AND METHODS: Data from the National Cancer Database were used. The pre- and post-PSP periods were identified as 2007-2009 and 2011-2013, respectively. Proportion differences (PDs) and 95% confidence Intervals (CIs) were calculated.
RESULTS: All three racial/ethnic groups experienced a statistically significant shift toward Stage I breast cancer. Pre-PSP, the black:white disparity in Stage I cancer was -9.5 (95% CI: -8.9, -10.4) and the Latina:white disparity was -5.2 (95% CI: -4.0, -6.1). Post-PSP, the disparities improved slightly. DISCUSSION: Preliminary data suggest that the ACA's PSP may have a meaningful impact on cancer stage overall and by race/ethnicity. However, more time may be needed to see reductions in disparities. Published by Elsevier Ltd.

Entities:  

Keywords:  Affordable care act; Breast cancer; Cancer stage; Disparities; Insurance

Mesh:

Year:  2017        PMID: 28601783      PMCID: PMC5544537          DOI: 10.1016/j.canep.2017.05.015

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  15 in total

1.  Promoting prevention through the Affordable Care Act.

Authors:  Howard K Koh; Kathleen G Sebelius
Journal:  N Engl J Med       Date:  2010-08-25       Impact factor: 91.245

2.  Controversies in Screening Mammography.

Authors:  Monique Swain; Myrlene Jeudy; Mark D Pearlman
Journal:  Clin Obstet Gynecol       Date:  2016-06       Impact factor: 2.190

3.  Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement.

Authors:  Albert L Siu
Journal:  Ann Intern Med       Date:  2016-01-12       Impact factor: 25.391

4.  Reduction in late-stage breast cancer incidence in the mammography era: Implications for overdiagnosis of invasive cancer.

Authors:  Mark A Helvie; Joanne T Chang; R Edward Hendrick; Mousumi Banerjee
Journal:  Cancer       Date:  2014-05-19       Impact factor: 6.860

5.  Patient navigator programs, cancer disparities, and the patient protection and affordable care act.

Authors:  Beverly Moy; Bruce A Chabner
Journal:  Oncologist       Date:  2011

6.  Racial and ethnic differences in use of mammography between Medicare Advantage and traditional Medicare.

Authors:  John Z Ayanian; Bruce E Landon; Alan M Zaslavsky; Joseph P Newhouse
Journal:  J Natl Cancer Inst       Date:  2013-12-06       Impact factor: 13.506

7.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

8.  Does utilization of screening mammography explain racial and ethnic differences in breast cancer?

Authors:  Rebecca Smith-Bindman; Diana L Miglioretti; Nicole Lurie; Linn Abraham; Rachel Ballard Barbash; Jodi Strzelczyk; Mark Dignan; William E Barlow; Cherry M Beasley; Karla Kerlikowske
Journal:  Ann Intern Med       Date:  2006-04-18       Impact factor: 25.391

9.  Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Authors:  William J Gradishar; Benjamin O Anderson; Ron Balassanian; Sarah L Blair; Harold J Burstein; Amy Cyr; Anthony D Elias; William B Farrar; Andres Forero; Sharon Hermes Giordano; Matthew Goetz; Lori J Goldstein; Clifford A Hudis; Steven J Isakoff; P Kelly Marcom; Ingrid A Mayer; Beryl McCormick; Meena Moran; Sameer A Patel; Lori J Pierce; Elizabeth C Reed; Kilian E Salerno; Lee S Schwartzberg; Karen Lisa Smith; Mary Lou Smith; Hatem Soliman; George Somlo; Melinda Telli; John H Ward; Dorothy A Shead; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2016-03       Impact factor: 11.908

10.  Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base.

Authors:  Karl Y Bilimoria; David J Bentrem; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

View more
  5 in total

1.  The Effects of Social and Behavioral Determinants of Health on the Relationship Between Race and Health Status in U.S. Breast Cancer Survivors.

Authors:  Yao Yuan; Monica Taneja; Avonne E Connor
Journal:  J Womens Health (Larchmt)       Date:  2018-12-19       Impact factor: 2.681

2.  The impact of the Patient Protection and Affordable Care Act on insurance coverage and cancer-directed treatment in HIV-infected patients with cancer in the United States.

Authors:  Kelsey L Corrigan; Leticia Nogueira; K Robin Yabroff; Chun Chieh Lin; Xuesong Han; Junzo P Chino; Anna E Coghill; Meredith Shiels; Ahmedin Jemal; Gita Suneja
Journal:  Cancer       Date:  2019-11-11       Impact factor: 6.860

3.  Association of Medicaid Expansion Under the Affordable Care Act With Stage at Diagnosis and Time to Treatment Initiation for Patients With Head and Neck Squamous Cell Carcinoma.

Authors:  Helmneh M Sineshaw; Mark A Ellis; K Robin Yabroff; Xuesong Han; Ahmedin Jemal; Terry A Day; Evan M Graboyes
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-03-01       Impact factor: 6.223

4.  Ethnicity and insurance status predict metastatic disease presentation in prostate, breast, and non-small cell lung cancer.

Authors:  Nima Aghdam; Mary McGunigal; Haijun Wang; Michael C Repka; Mihriye Mete; Stephen Fernandez; Chiranjeev Dash; Waddah B Al-Refaie; Keith R Unger
Journal:  Cancer Med       Date:  2020-06-08       Impact factor: 4.452

5.  Breast Cancer Risk Among Women in Jail.

Authors:  Michelle L Pickett; Molly Allison; Katelyn Twist; Jennifer R Klemp; Megha Ramaswamy
Journal:  Biores Open Access       Date:  2018-09-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.